NASDAQ:AXGN - AxoGen Stock Price, Forecast & News

AxoGen trades on the NASDAQ under the ticker symbol "AXGN."

AxoGen, Inc (NASDAQ:AXGN) posted its earnings results on Monday, February, 24th. The medical equipment provider reported ($0.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.09) by $0.01. The medical equipment provider had revenue of $28.16 million for the quarter, compared to analysts' expectations of $28.10 million. AxoGen had a negative net margin of 27.30% and a negative return on equity of 19.53%. AxoGen's quarterly revenue was up 20.2% on a year-over-year basis. During the same period last year, the firm posted ($0.09) earnings per share. View AxoGen's Earnings History.

AxoGen is scheduled to release their next quarterly earnings announcement on Wednesday, May 13th 2020. View Earnings Estimates for AxoGen.

AxoGen updated its FY 2020 After-Hours earnings guidance on Monday, February, 24th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $124-128 million, compared to the consensus revenue estimate of $131.75 million.

5 equities research analysts have issued twelve-month price objectives for AxoGen's stock. Their forecasts range from $21.00 to $28.00. On average, they anticipate AxoGen's stock price to reach $23.00 in the next twelve months. This suggests a possible upside of 77.2% from the stock's current price. View Analyst Price Targets for AxoGen.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AxoGen.

News articles about AXGN stock have been trending negative on Friday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. AxoGen earned a daily sentiment score of -2.8 on InfoTrie's scale. They also assigned news stories about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for AxoGen.

AxoGen saw a drop in short interest during the month of February. As of February 14th, there was short interest totalling 1,500,000 shares, a drop of 9.6% from the January 30th total of 1,660,000 shares. Based on an average trading volume of 331,700 shares, the days-to-cover ratio is currently 4.5 days. Currently, 4.2% of the shares of the company are short sold. View AxoGen's Current Options Chain.

Some companies that are related to AxoGen include InMode (INMD), Natus Medical (NTUS), Zynex (ZYXI), TransMedics Group (TMDX), Semler Scientific (SMLR), Cutera (CUTR), BioLife Solutions (BLFS), Viewray (VRAY), Stereotaxis (STXS), Rockwell Medical (RMTI), Fonar (FONR), Soleno Therapeutics (SLNO), Edap Tms (EDAP), BioSig Technologies (BSGM) and Second Sight Medical Products (EYES).

Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Intelsat (I), Exelixis (EXEL), Advanced Micro Devices (AMD), Xilinx (XLNX), Bank of America (BAC), Corbus Pharmaceuticals (CRBP), Crispr Therapeutics (CRSP), Micron Technology (MU), Amarin (AMRN) and NVIDIA (NVDA).

AxoGen's stock is owned by many different of institutional and retail investors. Top institutional investors include ArrowMark Colorado Holdings LLC (15.15%), Baillie Gifford & Co. (2.61%), State Street Corp (2.55%), William Blair Investment Management LLC (2.34%), Bank of New York Mellon Corp (2.22%) and Bank of America Corp DE (2.21%). Company insiders that own AxoGen stock include Amy Mcbride Wendell, Daniel Pietrzak, David K Hansen, Gregory Gene Freitag, Isabelle Billet, Karen L Zaderej, Michael Patrick Donovan, Quentin S Blackford and Shawn F Mccarrey. View Institutional Ownership Trends for AxoGen.

AXGN stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Bank of New York Mellon Corp, Renaissance Technologies LLC, Peregrine Capital Management LLC, Goldman Sachs Group Inc., Penn Capital Management Co. Inc., Perkins Capital Management Inc. and BerganKDV Wealth Management LLC. Company insiders that have sold AxoGen company stock in the last year include David K Hansen and Michael Patrick Donovan. View Insider Buying and Selling for AxoGen.

AXGN stock was acquired by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, William Blair Investment Management LLC, Point72 Asset Management L.P., Bank of America Corp DE, Bank of Montreal Can, Jacobs Levy Equity Management Inc., Granite Investment Partners LLC and Baillie Gifford & Co.. Company insiders that have bought AxoGen stock in the last two years include Amy Mcbride Wendell, Daniel Pietrzak, Isabelle Billet, Karen L Zaderej and Quentin S Blackford. View Insider Buying and Selling for AxoGen.

Shares of AXGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AXGN stock can currently be purchased for approximately $12.98.

AxoGen has a market capitalization of $515.70 million and generates $106.71 million in revenue each year. The medical equipment provider earns $-22,400,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. View Additional Information About AxoGen.

The official website for AxoGen is http://www.axogeninc.com/.

AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The medical equipment provider can be reached via phone at 386-462-6800 or via email at [email protected]